| Dermatitis, Atopic
Nemluvio vs Opzelura
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Nemluvio vs Opzelura with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOpzelura has a higher rate of injection site reactions vs Nemluvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Opzelura but not Nemluvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nemluvio
Opzelura
At A Glance
SC injection
Every 4 weeks
IL-31 receptor antagonist
Topical
Twice daily
JAK inhibitor
Indications
- Prurigo nodularis
- Dermatitis, Atopic
- Dermatitis, Atopic
- Vitiligo
Dosing
Prurigo nodularis (<90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks.
Prurigo nodularis (>=90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 60 mg SC every 4 weeks.
Dermatitis, Atopic Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks; after 16 weeks, patients who achieve clear or almost clear skin may receive 30 mg every 8 weeks.
Dermatitis, Atopic Apply a thin layer topically twice daily to affected areas of up to 20% body surface area; do not use with occlusive dressings; adults and pediatric patients 12 years and older: max one 60 gram tube per week or one 100 gram tube per 2 weeks; pediatric patients 2 to 11 years: max one 60 gram tube per 2 weeks.
Vitiligo Apply a thin layer topically twice daily to affected areas of up to 10% body surface area; max one 60 gram tube per week or one 100 gram tube per 2 weeks.
Contraindications
- Known hypersensitivity to nemolizumab-ilto or any excipient in NEMLUVIO
—
Adverse Reactions
Most common (>=1%) Headache, dermatitis atopic, eczema, eczema nummular (prurigo nodularis trials); headache, arthralgia, urticaria, myalgia (atopic dermatitis trials).
Serious Type 1 hypersensitivity reactions (IgE-mediated), including facial angioedema.
Most common (>=1%) - Atopic Dermatitis nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea, upper respiratory tract infection, COVID-19, application site reactions, pyrexia, white blood cell decreased
Most common (>=1%) - Nonsegmental Vitiligo application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia
Pharmacology
Nemolizumab-ilto is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by binding selectively to IL-31 receptor alpha (IL-31 RA); IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation, and fibrosis.
Ruxolitinib is a JAK inhibitor that inhibits JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function; JAK signaling involves STAT recruitment to cytokine receptors, activation, and nuclear localization leading to modulation of gene expression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nemluvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Opzelura
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Nemluvio
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (4/8)
Opzelura
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Nemluvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Opzelura
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NemluvioView full Nemluvio profile
OpzeluraView full Opzelura profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.